申请人:IMPACT THERAPEUTICS (SHANGHAI), INC
公开号:US11345711B2
公开(公告)日:2022-05-31
Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I:
or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.
所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物,具体由式 I 表示:
或其药学上可接受的盐或原药,其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此,本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。